FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides FDA Peptide Reclassification 2026: What Researchers Want Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA's new guidelines on bulk drug compounding Pharmacy & Healthcare Legal Blog FDA Peptide Reclassification 2026: What Researchers Want